Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Cyclopharm.
RELATED STOCKHEAD STORIES
News
Rise and Shine: Everything you need to know before the ASX opens
Health & Biotech
The next Neuren? These ASX biotech stocks have pending FDA catalysts in 2024
Health & Biotech
ASX Health Stocks: Neuren Pharma to begin Phase 2 clinical trial of children with Pitt Hopkins syndrome
Health & Biotech
ScoPo’s Powerplays: ASX health stocks fall but Dimerix up 150% on drug licensing deal
News
Market Highlights: ASX Futures down after a wild weekend in Washington, and 5 ASX small caps to watch today
News
CLOSING BELL: CBA makes bank from rising rates, then issues a warning about mortgage arrears
Health & Biotech
ASX Health Stocks: Cyclopharm confident after US FDA inspection; Anteris a step closer to FDA approval
Health & Biotech
These were the best ASX biotechs as Health Care sprang back to life in FY23
Experts
CRITERION: This ASX biotech is the sole dedicated player in a new $420 billion market
Health & Biotech
ASX Health Stocks: The US FDA will pay a visit to Cyclopharm’s facility in NSW
News
Market Highlights: Markets brace for more headwinds, and 5 ASX small caps to watch on Tuesday
Health & Biotech
ASX Health Stocks: Cyclopharm sends reply to FDA, the final step before potential approval
News
Market highlights and 5 ASX small caps to watch on Wednesday
Health & Biotech
ASX Health Stocks: FDA to expedite submission for Botanix’s sweaty armpits gel
Health & Biotech
Check Up: These biotech themes got billions in VC funding. These ASX stocks could benefit
Health & Biotech
Check Up: Johnson & Johnson manoeuvre causes a stir, as CSL pulls Healthcare higher on the ASX
Health & Biotech
